Clinical Trial Update: Safety and Tolerability Study of rBet v1 SLIT Tablets [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of recombinant Bet v 1 sublingual immunotherapy tablets (rBet v1 SLIT) in individuals with birch pollen-related allergic r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• rBet v1 SLIT tablets (recombinant Bet v 1 sublingual immunotherapy tablets)

Snippet

Sponsor: Stallergenes Greer | Conditions: Birch Pollen-Related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal | Phase 1 | Status: COMPLETED